-
-
-
-
-
-
-
Amgen (AMGN) Announces New Data Being Presented At ASH 2020
-
-
-
-
-
-
-
Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting
-
-
-
-
-
-
-
Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
-
-
-
-
-
-
-
Amgen (AMGN) Announces FDA Approves Addition Of Positive OS Data From Phase 3 ASPIRE Trial To KYPROLIS Label
-
-
-
-
-
-
-
Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label
-
-
-
-
-
-
-
Amgen (AMGN) Says Phase 3 A.R.R.O.W. Study of Once-Weekly KYPROLIS Regimen Meet Primary Endpoint of Progression-Free Survival In R/R Multiple Myeloma Patients
-
-
-
-
-
-
-
Amgen (AMGN) Submits sNDA in US And Europe to Include Overall Survival Data in KYPROLIS Label
-
55,525 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All